Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy

• Miso Kim,

  Affiliation Division of Hematology/Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

  ⨯
• Ja Hyeon Ku,

  Affiliation Department of Urology, Seoul National University Hospital, Seoul, Korea

  ⨯
• Cheol Kwak,

  Affiliation Department of Urology, Seoul National University Hospital, Seoul, Korea

  ⨯
• Hyeon Hoe Kim,

  Affiliation Department of Urology, Seoul National University Hospital, Seoul, Korea

  ⨯
• Eunsik Lee,

  Affiliation Department of Urology, Seoul National University Hospital, Seoul, Korea

  ⨯
• Bhumsuk Keam,

  Affiliations Division of Hematology/Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

  ⨯
• Tae Min Kim,

  Affiliations Division of Hematology/Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

  ⨯
• Dae Seog Heo,

  Affiliations Division of Hematology/Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

  ⨯
• Se-Hoon Lee ,

  Contributed equally to this work with: Se-Hoon Lee, Kyung Chul Moon

  Affiliation Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  ⨯
• Kyung Chul Moon

  Contributed equally to this work with: Se-Hoon Lee, Kyung Chul Moon

  * E-mail: blue7270@snu.ac.kr

  Affiliation Department of Pathology, Seoul National University Hospital, Seoul, Korea

  ⨯